LARK.ST Novakand Pharma AB (publ)

Financial Services Asset Management Stockholm Exchange
2.26 SEK
Close of Nov 7, 2026
1.75 2.60
Market cap
SEK 44.8M
P/E
37.7x
P/B
0.79x
ROE
4.3%
Dividend yield
8.85%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is LARK.ST undervalued?

Graham number
Price2.26
Graham value1.96
Premium15.2%

LARK.ST trades 15.2% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Novakand Pharma AB (publ) fundamental analysis

No fundamental analysis for Novakand Pharma AB (publ) yet.

Novakand Pharma AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Novakand Pharma AB (publ)

Lärkberget AB (publ) operates as an investment company. The company is involved in direct investments in low-risk instruments, and unlisted profitable companies; financial investments; and reverse acquisition business. It also invests in listed shares, funds and other liquid asset classes, as well as participates in bridge loans and guarantee commitments. The company was formerly known as CombiGene AB (publ) and changed its name to Lärkberget AB (publ) in June 2025. Lärkberg…

Full company profile